Kraig Biocraft Commissions New Spider Silk Production Center, Boosting Scale-Up Efforts
summarizeSummary
Kraig Biocraft Laboratories has commissioned a new recombinant spider silk production rearing center, which is already operational and supporting its April/May production cycle. This strategic expansion follows the company's recent announcement of converting a record 1.8 metric tons of spider silk and a recent equity offering to support growth. The new facility is expected to contribute to setting new production records and significantly accelerate the company's progress towards commercial-scale spider silk output. This move enhances both production capacity and operational resilience through a multi-facility strategy. Investors should monitor the company's continued deployment of additional production capacity throughout 2026 and its progress in achieving full commercialization targets.
At the time of this announcement, KBLB was trading at $0.14 on OTC in the Life Sciences sector, with a market capitalization of approximately $159.3M. The 52-week trading range was $0.07 to $0.16. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.